Updated

Popular GLP-1 weight loss drugs such as Ozempic and Wegovy are facing fresh scrutiny after researchers linked them to unexpectedly high rates of nail detachment, hair loss, and scalp inflammation that weight loss alone cannot fully explain. Separately, ongoing lawsuits allege the drugs can cause more serious harms, including blindness and pancreatitis, though scant adverse-event data makes it difficult to determine how often such harms occur. The twin developments add to growing questions about the long-term safety profile of the widely used GLP-1 drug class as its popularity and litigation both continue to rise.